HealthcareServices

Revenue of the Hematologic Malignancies Testing Market Predicted to Achieve $6.67 Billion by 2030, Driven by 13.2% CAGR

February 25, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the hematologic malignancies testing market from 2026–2035 with trusted insights from The Business Research Company

What level of CAGR-driven expansion is anticipated in the Hematologic Malignancies Testing Market between 2026 and 2030?

The hematologic malignancies testing market has experienced significant expansion recently. Its value is forecast to climb from $3.58 billion in 2025 to $4.06 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 13.4%. This historical rise can be attributed to the increasing prevalence of hematologic cancers, the broader implementation of molecular diagnostics, the enlargement of diagnostic laboratory networks, the growing application of CBC and flow cytometry, and enhanced availability of oncology testing services.

The hematologic malignancies testing market is projected for substantial expansion in the coming years, with its size expected to reach $6.68 billion by 2030, growing at a compound annual growth rate (CAGR) of 13.2%. This anticipated growth during the forecast period is primarily driven by escalating demand for precision oncology diagnostics, the increasing incorporation of AI-based data interpretation, the broadening scope of companion diagnostics, the growing adoption of MRD monitoring, and heightened investments in advanced diagnostic technologies. Furthermore, key trends anticipated for this period include the wider adoption of NGS-based diagnostic testing, a surge in the application of flow cytometry for MRD detection, the expanding integration of molecular and genetic assays, the development of personalized diagnostic profiling, and a greater emphasis on early and precise subtyping.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24234&type=smp

What Drivers Are Affecting Demand-Supply Dynamics In The Hematologic Malignancies Testing Market?

The anticipated expansion of the hematologic malignancies testing market is connected to the increasing number of cancer diagnoses. Cancer diagnosis refers to the process of identifying the presence, type, and stage of cancer in a patient through various medical tests and evaluations, including imaging, laboratory tests, and biopsies. The rise in cancer diagnoses is attributed to improved access to screening programs and greater public awareness, leading to earlier detection. Hematologic malignancies testing is instrumental in cancer diagnoses by enabling early detection, accurate classification, and monitoring of blood-related cancers, ultimately guiding targeted treatment decisions and improving patient outcomes. For instance, according to American Cancer Society, an US-based nonprofit organization, in 2024, over 2 million new cancer cases were diagnosed in the US, representing a 4% increase from previous years. Therefore, the growing number of cancer diagnoses is a key driver for the hematologic malignancies testing market.

What Segments Are Included Within The Hematologic Malignancies Testing Market?

The hematologic malignancies testing market covered in this report is segmented –

1) By Test Type: Complete Blood Count (CBC), Flow Cytometry, Molecular Testing, Genetic Testing, Others Test Type

2) By Product: Kits, Services

3) By Technology: Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Immunohisto Chemistry (IHC), Cytogenetics, Others Technology

4) By Therapeutic Indication: Leukemia, Lymphoma, Multiple Myeloma, Myeloproliferative Neoplasms, Others Therapeutic Indication

5) By End User: Hospitals, Diagnostic Labs, Academic and Research Institutions, Others End Users

Subsegments:

1) By Complete Blood Count (CBC): Hemoglobin Testing, Hematocrit Measurement, White Blood Cell Count, Red Blood Cell Count, Platelet Count, Mean Corpuscular Volume (MCV), Mean Corpuscular Hemoglobin (MCH)

2) By Flow Cytometry: Immunophenotyping, Cell Cycle Analysis, Apoptosis Detection, Minimal Residual Disease (MRD) Testing, DNA Content Analysis

3) By Molecular Testing: Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Reverse Transcriptase-PCR (RT-PCR), Fluorescence In Situ Hybridization (FISH), Microarray Analysis

4) By Genetic Testing: Germline Mutation Testing, Somatic Mutation Testing, Cytogenetic Testing, Chromosomal Aberration Detection, Single Nucleotide Polymorphism (SNP) Analysis

5) By Others Test Type: Bone Marrow Biopsy, Immunohistochemistry (IHC), Enzyme Assays, Serum Protein Electrophoresis (SPEP), Imaging Tests

What Upcoming Trends Are Likely To Define The Future Path Of The Hematologic Malignancies Testing Market?

Major companies engaged in the hematologic malignancies testing market are focused on developing innovative diagnostic methodologies, such as rapid molecular profiling, to offer healthcare providers precise and timely diagnostic tools. These tools aim to enhance early detection, treatment planning, and monitoring of blood cancers. Rapid molecular profiling is a diagnostic approach that analyzes a patient’s genetic makeup to identify mutations and variations, enabling faster and more personalized treatment decisions. For instance, in November 2023, Roswell Park Comprehensive Cancer Center, a US-based comprehensive cancer center, launched PanHeme. This next-generation gene sequencing tool is designed to diagnose hematologic cancers like leukemia, lymphoma, and multiple myeloma with greater accuracy and speed. The test identifies mutations in hundreds of genes in under 72 hours, significantly improving the speed and precision of diagnosis and ultimately guiding more personalized treatment decisions for patients.

Who Are The Core Companies Influencing Trends In The Hematologic Malignancies Testing Market?

Major companies operating in the hematologic malignancies testing market are Abbott Laboratories, F. Hoffmann-La Roche Ltd, Siemens Healthineers AG, Becton Dickinson and Company, Bio-Rad Laboratories Inc., Agilent Technologies Inc., Illumina Inc., Thermo Fisher Scientific Inc., Danaher Corporation, Sysmex Corporation, QIAGEN N.V., PerkinElmer Inc., Adaptive Biotechnologies Corporation, Invivoscribe Inc., ArcherDx Inc., Guardant Health Inc., Sophia Genetics SA, Natera Inc., Roche Diagnostics International AG, Laboratory Corporation of America Holdings

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/hematologic-malignancies-testing-global-market-report

Which Region Is Expected To Experience The Fastest Growth In The Hematologic Malignancies Testing Market?

North America was the largest region in the hematologic malignancies testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hematologic malignancies testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Hematologic Malignancies Testing Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24234&type=smp

Browse Through More Reports Similar to the Global Hematologic Malignancies Testing Market 2026, By The Business Research Company

Hematology Diagnostic Devices And Equipment Market Report 2026

https://www.thebusinessresearchcompany.com/report/hematology-diagnostic-devices-and-equipment-global-market-report

Dermatological Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/dermatological-drugs-global-market-report

Hematocrit Test Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/hematocrit-test-devices-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795